CURRENT STATUS
Teplizumab (Tzield) delays onset by 2+ years. Vertex stem cell-derived islets (VX-880) showing insulin independence in trials. CRISPR immune-evasion strategies advancing.
KEY BREAKTHROUGHS
Teplizumab (Tzield) — first drug to delay T1D onset, FDA-approved 2022
Vertex VX-880 stem cell-derived islets — patients achieving insulin independence in trials
CRISPR-edited hypoimmune stem cells evading rejection without immunosuppression
AI-designed closed-loop artificial pancreas systems achieving near-normal glucose control
AI-COMPRESSED PIPELINE
AI TOOLS ACCELERATING CURES
Immune Profiling AIBeta Cell Differentiation OptimizationAutoimmune Prediction ModelsSmart Insulin Delivery
KEY ORGANIZATIONS
Vertex PharmaceuticalsSana BiotechnologyProvention BioNovo NordiskJDRF
TIMELINE ESTIMATE
Functional cure (stem cell islets): 3–5 years to broad availability. Full immune reset: 5–8 years.